<DOC>
	<DOC>NCT02244216</DOC>
	<brief_summary>Study to obtain data about changing from the chlorofluorocarbon (CFC) - containing Berotec® 200 µg metered - dose inhaler to the CFC - free Berotec® N 100 µg metered - dose inhaler</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<criteria>Patients were included in the study only if they had been treated with Berotec® 200 µg metered dose inhaler before switching to the CFCfree Berotec® N 100 µg metered dose inhaler • Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berotec® N 100 µg metered dose inhaler</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>